<a href="https://www.fiercebiotech.com/biotech/cellcentric-announces-220m-series-d-advance-drug-through-registration-and-potential-ipo" hreflang="en">CellCentric raises $220M series D to advance myeloma drug through registration, eyes potential IPO</a>
CellCentric has secured $220 million in a Series D funding round to advance its myeloma drug, inobrodib, through registration trials, with the potential for an IPO in the future. The funding will support ongoing clinical trials and allow the company to operate independently, focusing on its drug development without the pressure of immediate partnerships or acquisitions.
CellCentric's $220 million Series D funding round positions the company to independently advance its myeloma drug, inobrodib, through clinical trials without dependency on external partnerships, highlighting both its potential IPO readiness and strategic autonomy. For a professional tracking healthtech investments, this signals a strong potential IPO opportunity and underscores the increasing value placed on biotech companies with promising clinical data and robust funding syndicates.